Orilissa Alternatives Compared
| Orilissa (elagolix) | Norethindrone | Lupron Depot (leuprolide) |
|
|---|
| Orilissa (elagolix) | Norethindrone | Lupron Depot (leuprolide) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Endometriosis. Orilissa may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Abnormal Uterine Bleeding, Endometriosis, Amenorrhea, Gender Affirming Hormone Therapy, Birth Control. Norethindrone may also be used for purposes not listed in this medication guide. |
Prescription only
Lupron Depot is a hormone deprivation treatment that may be used for the palliative care of advanced prostate cancer. The main side effects are hot flashes and general pain and it may cause... View more |
Related suggestions Endometriosis
Popular comparisons
|
|||||||||||||||||||||||
| More about Orilissa (elagolix) | More about Norethindrone | More about Lupron Depot (leuprolide) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Orilissa has an average rating of 5.4 out of 10 from a total of 128 ratings on Drugs.com. 40% of reviewers reported a positive effect, while 40% reported a negative effect. |
Norethindrone has an average rating of 4.9 out of 10 from a total of 1571 ratings on Drugs.com. 33% of reviewers reported a positive effect, while 45% reported a negative effect. |
Lupron Depot has an average rating of 5.8 out of 10 from a total of 231 ratings on Drugs.com. 44% of reviewers reported a positive effect, while 32% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
View all Orilissa side effects |
View all Norethindrone side effects |
View all Lupron Depot side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
Lower cost generic |
||||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Orilissa prices |
View all Norethindrone prices |
View all Lupron Depot prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
|
N/A |
Affodel, Camila, Deblitane, Emzahh, Errin, Gallifrey, Heather, Incassia, Jencycla, Lyleq, Lyza, Meleya, Nor-QD, Norlyda, Norlyroc, Orquidea, Sharobel, Tulana View more | Other leuprolide brands include: Camcevi, Eligard, Fensolvi, Lupron, Lupron Depot-PED, Lutrate Depot | ||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
6 hours |
10 hours |
4.25 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category X
Not for use in pregnancy
See the full pregnancy warnings document. |
Category X
Not for use in pregnancy
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 372 drugs are known to interact with Orilissa:
|
A total of 267 drugs are known to interact with Norethindrone:
|
A total of 282 drugs are known to interact with Lupron Depot:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
July 23, 2018 |
April 21, 1982 |
January 26, 1989 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.